Summit Therapeutics (SMMT) News Today → A letter is coming from the 'Bureau of the Fiscal Service'. (From Stansberry Research) (Ad) Free SMMT Stock Alerts $4.44 -0.07 (-1.55%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 9, 2024 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Coverage Initiated at CitigroupMay 8, 2024 | seekingalpha.comSummit: A Few Catalysts In Q2 Of 2024 To Carry The TideMay 8, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Sets New 1-Year High at $5.39Summit Therapeutics (NASDAQ:SMMT) Reaches New 52-Week High at $5.39May 7, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Up 8.7%Summit Therapeutics (NASDAQ:SMMT) Stock Price Up 8.7%May 7, 2024 | msn.comSummit spikes as Citi launches at Buy on lead assetMay 7, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Coverage Initiated by Analysts at CitigroupCitigroup assumed coverage on Summit Therapeutics in a research report on Tuesday. They set a "buy" rating and a $7.00 target price on the stock.May 2, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.6%Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.6%May 2, 2024 | finance.yahoo.comSummit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call TranscriptMay 2, 2024 | finance.yahoo.comSummit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...May 1, 2024 | investorplace.comSMMT Stock Earnings: Summit Therapeutics Reported Results for Q1 2024May 1, 2024 | finance.yahoo.comSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024April 30, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Trading 3.6% Higher Summit Therapeutics (NASDAQ:SMMT) Trading Up 3.6%April 25, 2024 | marketbeat.comSummit Therapeutics (SMMT) Scheduled to Post Quarterly Earnings on WednesdaySummit Therapeutics (NASDAQ:SMMT) will be releasing earnings before the market opens on Wednesday, May 1, Zacks reports.April 24, 2024 | businesswire.comSummit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024April 23, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Up 10.6%Summit Therapeutics (NASDAQ:SMMT) Stock Price Up 10.6%April 13, 2024 | marketbeat.comShort Interest in Summit Therapeutics Inc. (NASDAQ:SMMT) Grows By 28.6%Summit Therapeutics Inc. (NASDAQ:SMMT - Get Free Report) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 21,810,000 shares, a growth of 28.6% from the March 15th total of 16,960,000 shares. Based on an average daily trading volume, of 2,340,000 shares, the short-interest ratio is presently 9.3 days. Currently, 26.3% of the company's stock are sold short.April 12, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.7%Summit Therapeutics (NASDAQ:SMMT) Trading Down 6.7%April 11, 2024 | finance.yahoo.comSummit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of DirectorsApril 11, 2024 | businesswire.comSummit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of DirectorsApril 10, 2024 | businesswire.comSummit Therapeutics to Present at the Stifel 2024 Targeted Oncology ForumApril 9, 2024 | reuters.comIllumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successorApril 9, 2024 | prnewswire.comIllumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development OfficerApril 4, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $3.95Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $3.95April 1, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 6%Summit Therapeutics (NASDAQ:SMMT) Trading Down 6%March 29, 2024 | investing.comSummit Therapeutics CEO acquires shares worth over $411kMarch 29, 2024 | fool.comWhy Summit Therapeutics Stock Crushed the Market This WeekMarch 29, 2024 | insidertrades.comInsider Buying: Summit Therapeutics Inc. (NASDAQ:SMMT) CEO Acquires 30,000 Shares of StockMarch 28, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Trading 18.9% Higher After Insider Buying ActivitySummit Therapeutics (NASDAQ:SMMT) Trading Up 18.9% Following Insider Buying ActivityMarch 27, 2024 | marketbeat.comInsider Buying: Summit Therapeutics Inc. (NASDAQ:SMMT) CEO Buys 30,000 Shares of StockSummit Therapeutics Inc. (NASDAQ:SMMT - Get Free Report) CEO Mahkam Zanganeh purchased 30,000 shares of the business's stock in a transaction dated Tuesday, March 26th. The shares were purchased at an average cost of $3.75 per share, with a total value of $112,500.00. Following the completion of the purchase, the chief executive officer now directly owns 30,000 shares in the company, valued at $112,500. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.March 26, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $3.28Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $3.28March 20, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Trading 5% Higher Summit Therapeutics (NASDAQ:SMMT) Shares Up 5%March 19, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 4.6%Summit Therapeutics (NASDAQ:SMMT) Trading Down 4.6%March 18, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $4.62Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $4.62March 14, 2024 | marketbeat.comSummit Therapeutics Inc. (NASDAQ:SMMT) Short Interest Up 25.1% in FebruarySummit Therapeutics Inc. (NASDAQ:SMMT - Get Free Report) saw a significant growth in short interest during the month of February. As of February 29th, there was short interest totalling 15,950,000 shares, a growth of 25.1% from the February 14th total of 12,750,000 shares. Approximately 19.2% of the company's shares are sold short. Based on an average trading volume of 1,940,000 shares, the days-to-cover ratio is currently 8.2 days.March 14, 2024 | businesswire.comIntracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024March 13, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Up 8.1%Summit Therapeutics (NASDAQ:SMMT) Trading Up 8.1%March 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMTMarch 5, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Up 6.7%Summit Therapeutics (NASDAQ:SMMT) Trading 6.7% HigherMarch 5, 2024 | businesswire.comSummit Therapeutics to Present at the Barclays 26th Annual Global Healthcare ConferenceMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMTFebruary 27, 2024 | msn.comSHAREHOLDER ALERT: Potential Recovery for Summit Therapeutics Inc. (SMMT) InvestorsFebruary 26, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $4.64Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $4.64February 26, 2024 | businesswire.comSummit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsFebruary 21, 2024 | uk.finance.yahoo.comSummit Therapeutics plc (SMMT)February 21, 2024 | finance.yahoo.comQ4 2023 Summit Therapeutics Inc Earnings CallFebruary 21, 2024 | finance.yahoo.comSummit Therapeutics Inc. (NASDAQ:SMMT) Q4 2023 Earnings Call TranscriptFebruary 20, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $5.07Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $5.07February 20, 2024 | finance.yahoo.comSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023February 20, 2024 | finance.yahoo.comSummit Therapeutics Inc (SMMT) Reports Comprehensive 2023 Financial Results and Clinical ...February 20, 2024 | businesswire.comSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023 Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon’s New Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. SMMT Media Mentions By Week SMMT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SMMT News Sentiment▼0.000.42▲Average Medical News Sentiment SMMT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SMMT Articles This Week▼01▲SMMT Articles Average Week Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Crinetics Pharmaceuticals News Today Biohaven News Today Axsome Therapeutics News Today Insmed News Today Ultragenyx Pharmaceutical News Today Prestige Consumer Healthcare News Today HUTCHMED News Today Alkermes News Today Perrigo News Today Xenon Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SMMT) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressMan who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.”InvestorPlaceCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsBuy this small stock before coming AI Tidal WaveChaikin AnalyticsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHow Biden has already won 2024Porter & CompanyUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
